Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Rare BTK mutation drives resistance to targeted therapies for blood cancer

27

Jul 2026

Rare BTK mutation drives resistance to targeted therapies for blood cancer

Scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a finding that could help shape the next generation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.

A common dietary nutrient feeds a gut pathway linked to atrial fibrillation

27

Jul 2026

A common dietary nutrient feeds a gut pathway linked to atrial fibrillation

Researchers linked higher plasma TMAO to prevalent atrial fibrillation in 5,090 people and found that TMAO or choline supplementation accelerated AF onset, progression, atrial remodeling, and electrical dysfunction in mice. Inhibiting gut microbial TMA production lowered circulating TMAO and delayed AF in mice, identifying a potential therapeutic pathway that now requires human testing.

NIH grant funds study on stroke-related urinary incontinence

27

Jul 2026

NIH grant funds study on stroke-related urinary incontinence

Urinary incontinence is a common but frequently overlooked consequence of stroke. Now, researchers from the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC and Rancho Los Amigos National Rehabilitation Center have received a grant from the National Institutes of Health to investigate the brain changes responsible for these symptoms and develop a more personalized approach to treatment.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.